Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840862 · ClinicalTrials.gov registry record · Phase 4
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor
A Phase 4 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT04840862: Completed Phase 4 study, sponsored by University of Southern California.
NCT04840862 is a Phase 4 study that has completed, run by University of Southern California. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04840862, a Phase 4 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.
Primary Outcome
To assess the impact of rifabutin on the AUC of ELX/TEZ/IVA
Interventions
- DRUG Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]
- DRUG Rifabutin 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 4 |
What the finished NCT04840862 record still lists
NCT04840862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg] is the first listed.
NCT04840862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04840862 about?
NCT04840862 is a clinical study titled "Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor". This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.
What is the current status of trial NCT04840862?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2022-05-09. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT04840862?
The interventions under investigation include: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg] (DRUG), Rifabutin 300mg (DRUG).
Who is sponsoring clinical trial NCT04840862?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04840862's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI